Sai Life Sciences to double process R&D capacity with new facility in Hyderabad
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Fully equipped labs with 75-member team set-up and made operational in <100 days
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
Subscribe To Our Newsletter & Stay Updated